- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Tafamidis – March 2026
Capsule 61 mg
Last updated
11 March 2026